The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. Interventions: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. Main Outcomes and Measures: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Results: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). Conclusions and Relevance: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. Trial Registration: clinicaltrials.gov identifier: NCT00265850.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, patients with metastatic colorectal cancer and related intestinal malignancies tend to receive similar treatments and live for many months with relatively stable health (median overall survival >2 years) [44], facilitating study completion and potentially derivation of durable benefit from the intervention.”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although a higher percentage of men enrolled compared to most prior mindfulness interventions for integrative cancer care [34], the evaluable study sample included a greater proportion of younger (age <50), female, White and Latino or Hispanic patients relative to the underlying population [44, 53].”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“This trial demonstrated that patients in the cetuximab plus chemotherapy group had slightly higher overall survival versus patients in the bevacizumab plus chemotherapy group (30.0 months versus 29.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similar to the FIRE-3 trial, median progression-free survival and response rates were similar between groups.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [21]
In the citing paper
“however, it must be noted here that this pooled analysis also included patients who had received a nonstandard treatment regimen, including FUFIRI, FUFOX, and mIROX as induction chemotherapies and bevacizumab monotherapy or observation alone as maintenance therapies in clinical trials [22,23].”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“a The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
MethodInfluentialSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Cited by
Sorted by citations
Items 501–600 of 900
The Current Role of Antiangiogenics in Colorectal Cancer
Basile, D., Nardo, P. D., Daffinà, M. G., Cortese, C., Giuliani, J., & Aprile, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311605 · Cited by 7
“…to include only RAS wild-type patients; it showed an equivalence between regimens in terms of OS (29.0 vs. 30.0 months for the chemotherapy/bevacizumab and chemotherapy/cetuximab combinations, respectively; HR 0.88; 95% C.I., 0.77–1.01; p = 0.08) and PFS (10.6 vs. 10.5 months, respectively) [55].”
InfluentialA high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer
Heinlein, M., Li, G. X., Kljavin, N. M., Moore, A. R., Biehs, B., Tao, L., Boumahdi, S., Mohammadi, F., Shi, M., Liang, Y., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01155-w · Cited by 7
Qi, C., Liu, C., Gong, J., Wang, X., Wang, Z., Xu, T., Liu, D., Zhang, P., Li, J., Zhang, M., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01090 · Cited by 7
Ramaswamy, A., Babu, V., Kothari, R. K., Abhinav, R., Desouza, A. L., Ventrapati, P., Kumar, A., Kapoor, A., Das, S., Engineer, R. Z., et al. (2022) · South Asian Journal of Cancer · doi:10.1055/s-0041-1736203 · Cited by 6
Avelumab in Patients With Metastatic Colorectal Cancer
Redman, J. M., Coyne, G. O., Reed, C. T., Madan, R. A., Strauss, J., Steinberg, S. J., Marté, J. L., Cordes, L. M., Heery, C. R., & Gulley, J. L. (2023) · The Oncologist · doi:10.1093/oncolo/oyad162 · Cited by 6
Song, Q., Wu, H., Jin, Y., Hou, J., Liu, J., Zhang, X., Hu, W., Sun, G., & Zhang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1503133 · Cited by 6
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer
Grancher, A., Beaussire, L., Vernon, V., Dutherage, M., Blondin, V., Elie, C., Bouhier‐Leporrier, K., Galais, M., Clabaut, T., Bignon, A.-L., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02971-0 · Cited by 6
Eastern Canadian Colorectal Cancer Consensus Conference 2017
McGee, S. F., Alghareeb, W. A., Ahmad, C. H., Armstrong, D. E., Babak, S., Berry, S. R., Biagi, J. J., Booth, C. M., Bossé, D., Champion, P., et al. (2018) · Current Oncology · doi:10.3747/co.25.4083 · Cited by 6
Self-citationAlfonso, P. G., González, G. G., Gallego, I., Peligros, M. I., Ortega, L., Pérez-Solero, G. T., Sandoval, C., Martín, Á., Codesido, M. B., Ferrándiz, A. C., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02402-x · Cited by 6
Childs, D. D., Lima, C. M. S. P. R., & Zhou, Y. (2020) · Seminars in Roentgenology · doi:10.1053/j.ro.2020.07.010 · Cited by 6
Zhang, X., Fu, S., Meng, R., Ren, Y., Shang, Y., & Tian, L. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2303 · Cited by 4
“(32) 2017 NA USA 559 BEV 1,2,3,4 5,8 NCT00265850”
Kimura, M., Usami, E., & Yoshimura, T. (2020) · Anticancer Research · doi:10.21873/anticanres.14743 · Cited by 6
Chemotherapy of metastatic colon cancer in France: A population-based study
Mas, L., Bachet, J., Jooste, V., Lepage, C., & Bouvier, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.03.019 · Cited by 7
Fang, T., Liang, T., Wang, Y., Wu, H., Liu, S., Xie, L., Zhang, Z., Liang, J., Cheng, Y., Tan, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755578 · Cited by 6
Han, Y. N., Choi, Y. J., & Rhie, S. J. (2022) · Healthcare · doi:10.3390/healthcare10020217 · Cited by 6
“2017) [13] November 2005– March 2012 United States and Canada Multicenter, randomized phase III study Patients aged ≥18 years with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt Bevacizumab (5 mg/kg) (n = 559) Cetuximab (400 mg/m2 followed by 250 mg/m2 weekly) (n = 578) mFOLFOX…”
BackgroundArchwamety, A., Teeyapun, N., Siripoon, T., Poungvarin, N., Tanasanvimon, S., Sirachainan, E., Akewanlop, C., & Korphaisarn, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.813009 · Cited by 6
Ortiz‐Morales, M. J., Toledano‐Fonseca, M., Mena‐Osuna, R., Cano‐Osuna, M. T., Gómez‐España, A., de la Haba-Rodríguez, J., Rodríguez‐Ariza, A., & Aranda, E. (2022) · Cancers · doi:10.3390/cancers14133054 · Cited by 6
“Survival rates for this disease depend on clinical, biological, and molecular prognostic factors, with median overall survival (OS) in metastatic disease exceeding 30 months [2,3].”
BackgroundRigault, E., Lacas, B., Gléhen, O., Smith, D. M., Dupont-Bierre, E., Guimbaud, R., Malka, D., Boige, V., Fuerea, A. C., Pignon, J., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100674 · Cited by 6
Erdoğan, B., Özcan, E., Gökmen, İ., Gökyer, A., Küçükarda, A., Köstek, O., Hacıoğlu, M. B., Uzunoğlu, S., & Çiçin, İ. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1620_21 · Cited by 6
Hammoudi, N., Lehmann‐Che, J., Lambert, J., Amoyel, M., Maggiori, L., Salfati, D., Tran‐Minh, M., Baudry, C., Asesio, N., Poirot, B., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.02.011 · Cited by 6
Cohen, S. A., Veleber, S., Siman, J., Guthrie, K. A., McMillen, K. K., Heit, M., Wadhera, S., Daniels, J., Hansen, K., Jacoby, M., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107273 · Cited by 6
Reißig, T. M., Ladigan‐Badura, S., Steinberg, A., Maghnouj, A., Li, T., Verdoodt, B., Liffers, S. T., Pohl, M., Wolters, H. H., Teschendorf, C., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13510 · Cited by 7
Melosky, B. L., Lim, H. J., Davies, J. M., Gill, S., Kollmannsberger, C., Ho, M. Y., Vandt, S. A., & Renouf, D. J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3738-x · Cited by 6
Rosati, G., Cordio, S. S., Reggiardo, G., Aprile, G., Butera, A., Avallone, A., Tucci, A., Novello, G., Blanco, G., Caputo, G., et al. (2019) · Cancers · doi:10.3390/cancers11040578 · Cited by 6
“With the advent of new targeted therapies, the median OS for all patients is approximately 30 months after diagnosis [28,29].”
BackgroundEvaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
Baek, S. K., Lee, K. T., Bae, S. B., & Lee, S. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.071 · Cited by 6
“Results showed that there was no significant difference in OS as primary endpoint between patients treated with cetuximab and those treated with bevacizumab combined with mFOLFOX6 or FOLFIRI as first-line therapy [42].”
BackgroundWu, W., Yang, X., Jiamin, X., Jing, Z., & Han, S. (2019) · RSC Advances · doi:10.1039/c9ra06146k · Cited by 6
Yoshida, Y., Kaneko, M., & Narukawa, M. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01619-8 · Cited by 6
Bieńkowska, A., Kuźmicka, W., Ciepiela, O., Ochocki, J., & Małecki, M. (2020) · BioMed Research International · doi:10.1155/2020/9107140 · Cited by 6
Shankaran, V., Unger, J. M., Darke, A. K., Hershman, D. L., & Ramsey, S. D. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106037 · Cited by 6
Elshenawy, M. A., Badran, A. A., Aljubran, A. H., Alzahrani, A., Rauf, M. S., Eldali, A., & Bazarbashi, S. N. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01930-8 · Cited by 6
Liver resection is beneficial for patients with colorectal liver metastases and extrahepatic disease
Lang, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4416 · Cited by 6
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
First-line treatment in metastatic colorectal cancer: Important or crucial?
Malka, D., Rotolo, F., & Boige, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.001 · Cited by 6
Cervantes, A. M. R., & Prager, G. W. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100883 · Cited by 7
Alfonso, P. G., Valladares‐Ayerbes, M., Martín, A. J. M., Herrero, R. M., Muñoz, E. G., & Prat-Llorens, G. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477192 · Cited by 5
Huang, N., Ren, J., Deng, X., Bao, Q., Huang, G., Zhi, S., Li, Y., Li, J., Hu, B., Zeng, D., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2551720 · Cited by 5
“Currently, chemotherapy combined with anti-angiogenesis therapy has been widely applied in the treatment of metastatic CRC (mCRC) [2,3].”
CACA guidelines for holistic integrative management of rectal cancer
Wang, G., Fan, D., Gu, J. F., Ding, K., Fang, X., Shen, L., Xu, Z., Xu, J., Cai, J., Cai, L., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00023-2 · Cited by 5
“For RAS / BRAF wild / MSS type tumors, FOLFOX / FOLFIRI combined with cetuximab is preferred [92, 93]; for RAS mutant, BRAF wild/MSS type or BRAF mutant /MSS type tumors intolerant to triple-drug chemotherapy, FOLFOX / CapeOx / FOLFIRI combined with bevacizumab is preferred; for young patients with a good performance…”
BackgroundLiu, C., Chen, J., & Liu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-86575-x · Cited by 5
RetractedNiedersüß‐Beke, D., Orlinger, M., Falch, D., Heiler, C., Piringer, G., Thaler, J., Hilbe, W., Petzer, A. L., & Rumpold, H. F. (2021) · Cancers · doi:10.3390/cancers13092091 · Cited by 5
“This number, however, reflects a specific patient population within clinical trials, which select patients with specific prognostically relevant markers [9,10].”
BackgroundAllart, M., Leroy, F., Kim, S. C. H., Sefrioui, D., Nayeri, M., Zaanan, A., Rousseau, B., Abdelghani, M. B., de la Fouchardière, C., Cacheux, W., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.031 · Cited by 5
Li, G., & Liu, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2280440 · Cited by 5
RetractedExpression of neurofibromin 1 in colorectal cancer and cetuximab resistance
Tak, E., Kim, M., Cho, Y.-R., Choi, S., Kim, J., Han, B., Kim, H., Jang, C. S., Kim, J. H., Hong, Y. S., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8226 · Cited by 6
“Therapeutic strategies for metastatic colorectal cancer (mCRC) have improved over the past number of decades, which resulted in prolonged patient survival for ≤3 years (2).”
BackgroundTherapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System
Javed, A., Malagraba, G., Yarmohammadi, M., Perelló-Reus, C. M., Barceló, C., & Rubio‐Tomás, T. (2022) · Future Pharmacology · doi:10.3390/futurepharmacol2030015 · Cited by 5
A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer
Jethwa, K. R., Jin, Z., & Hallemeier, C. L. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.06.084 · Cited by 5
Ito, T., Takashima, A., Yamazaki, K., Yukami, H., Uetake, H., Tsuda, M., Suto, T., Moriwaki, T., Sugimoto, N., Ojima, H., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02208-7 · Cited by 5
Österlund, E., & Glimelius, B. L. G. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2126327 · Cited by 5
“Better OS in the most recent trials compared to those reported 10 – 15 years ago [6,8,38] can probably be explained by either more optimal use of the drugs or better patient selection with exclusion of patient groups/tumour types with the worst survival.”
Qu, F.-J., Wu, S., & Kong, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.902 · Cited by 5
Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)
Brown, J. C., Ma, C., Shi, Q., Zemla, T., Couture, F., Kuebler, P. J., Kumar, P., Tan, B. R., Krishnamurthi, S., Chang, V. T.-S., et al. (2023) · Cancer · doi:10.1002/cncr.35007 · Cited by 5
Self-citationLecomte, T., Giraudeau, B., Phelip, J.-M., Tournigand, C., Ducreux, M. P., Tougeron, D., Lepage, C., Mineur, L., Laplaige, P., Desgrippes, R., et al. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.02.002 · Cited by 5
Germani, M. M., Heinemann, V., Rossini, D., von Weikersthal, L. F., Pietrantonio, F., Heinrich, K., Stahler, A., Lonardi, S., Kaiser, F., Decker, T. W., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.001 · Cited by 7
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
Martínez‐Pérez, J., Martínez, M. C. R., & García‐Carbonero, R. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1475557 · Cited by 5
Hayashi, K., Mitani, S., Taniguchi, H., Yasui, H., Muro, K., Mori, K. P., Gotoda, T., & Yamazaki, K. (2018) · Oncology · doi:10.1159/000493321 · Cited by 5
Expressions of CD23, IL-17 and MMP-9 in Patients with Colorectal Cancer
Guo, X., Gang, L. I. U., Xie, X., Jing, L. I., Hou, Z., Zehui, H. O. U., Gu, Y., & Yu, L. (2020) · Iranian Journal of Public Health · doi:10.18502/ijph.v49i2.3088 · Cited by 5
“Once the patient is diagnosed, colorectal cancer has already been in advanced period, during this time, cancer cells have generally spread and metastasized, which makes it difficult to treat colorectal cancer by resection (6, 7) and is one of the reasons why the prognosis of colorectal cancer is poor.”
BackgroundAnalysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer
Yu, Z., Wang, J., Cai, X., Gao, Z., Wang, S., & Gu, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1095 · Cited by 4
“0 months in the bevacizumab group (18).”
Zhao, N., Cao, Y., Yang, J., Li, H., Wu, K., Wang, J., Peng, T., & Cai, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.582244 · Cited by 5
Wu, C., Wang, J., Chang, M., Chen, Y., Wang, Y.-C., Lee, M.-H., Lin, C.-Y. E., Su, Y., Lin, P., & Hsu, C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211020806 · Cited by 5
“The National Comprehensive Cancer Network treatment guidelines recommend bevacizumab, panitumumab, and cetuximab for RAS WT left-sided mCRC, with a clear preference for panitumumab and cetuximab.(34) Biomarker analysis is critical for selecting patients for therapy using an EGFR inhibitor.”
MethodYin, J., Dawood, S. S., Cohen, R., Meyers, J., Zalcberg, J. R., Yoshino, T., Seymour, M., Maughan, T., Saltz, L. B., Cutsem, E. V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211020547 · Cited by 5
Self-citationLi, D., Wang, F., Xu, S., Li, K., Meng, X., Huang, Y., Ma, N., Qiao, L., Kuang, G., Chen, J., et al. (2021) · Journal of Cancer · doi:10.7150/jca.60014 · Cited by 5
“Although there were inconsistent data on which is the optimal choice of the first-line targeted therapy [10, 11], recent studies in analyzing 2,576 mCRC patients from two randomized controlled trials and three prospective cohorts indicate that cetuximab provides better clinically relevant effects than bevacizumab [12].”
BackgroundEinfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2021) · Der Chirurg · doi:10.1007/s00104-021-01486-7 · Cited by 5
Cerebellar metastasis of colon cancer at diagnosis
Şimşek, M., & Deveci, M. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_514_20 · Cited by 5
Özçelik, M., Oyman, A., Çil, İ., Düzgün, Ö., Özkan, Ö. F., & Ayhan, M. (2021) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2021.11.1308 · Cited by 5
Chennamadhavuni, A., & Kasi, P. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847299 · Cited by 5
Choi, Y. J., Choi, C.-Y., Rhie, S. J., & Shin, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159196 · Cited by 6
“The backbone chemotherapy regimens were FOLFOX [27,28,30,31], FOLFIRI [28,29,31–33], and irinotecan [34].”
Takahashi, S. I., Ouchi, K., Sakamoto, Y., Mori, T., Shimodaira, H., Takahashi, M., Ohori, H., Kudo, C., Takahashi, Y., Imai, H., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-862 · Cited by 5
The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
Ruff, S. M., Shannon, A. H., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15133513 · Cited by 5
Price, T. J., Shen, L., Ma, B. B. Y., Esser, R., Chen, W., Gibbs, P., Lim, R. S. C., & Cheng, A. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13154 · Cited by 5
Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma
Vittal, A., Sharma, D., Samanta, I., & Kasi, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2017-221816 · Cited by 7
Palmieri, L., Mineur, L., Tougeron, D., Rousseau, B., Granger, V., Gornet, J., Smith, D. M., Lièvre, A., Galais, M., Doat, S., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0328 · Cited by 5
“The CALGB/SWOG 80405 trial [3] identified no differences in terms of median progression-free survival (PFS) or overall survival (OS) in patients receiving 5-FU-based doublet chemotherapy plus either bevacizumab or cetuximab.”
for PRODIGE investigators/collaborators, Aparicio, T., Bennouna, J., Malicot, K. L., Boige, V., Taı̈eb, J., Bouché, O., Phelip, J., François, É., Borel, C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0735-8 · Cited by 5
Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
Pasquale, M. D. D., Crocoli, A., Caldaro, T., Rinelli, M., Spinelli, G. P., Francalanci, P., Cozza, R., Inserra, A., & Miele, E. (2020) · Cancers · doi:10.3390/cancers12020414 · Cited by 5
FOLFOXIRI reintroduction in metastatic colorectal cancer
Glynne‐Jones, R., & Harrison, M. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30087-5 · Cited by 5
Chang, G. J. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00057 · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
Delphi consensus for the third-line treatment of metastatic colorectal cancer
Alfonso, P. G., Vera, R., Aranda, E., Élez, E., & Rivera, F. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03369-1 · Cited by 4
Pakvisal, N., Pappas, L., Caughey, B. A., Horick, N., Tarazona, N., Vora, K. B., Ouyang, B., Pandey, A., Peacker, B. L., Sun, J., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0690 · Cited by 4
“Current first-line treatment with chemotherapy plus anti-EGFR or anti-VEGF therapies (3) provides disease control for 10 to 13 months (10–12), whereas later-line regimens such as regorafenib or trifluridine/tipiracil with bevacizumab offer only modest survival benefit (13–15), underscoring the…”
Li, W., Peng, J., He, J., Liao, L., Kang, D., Zhang, W., Wang, W., Wang, R., Wang, S., Liao, Y., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3520 · Cited by 4
“The application of doublet or triplet chemotherapy regimens with antiangiogenic therapy such as bevacizumab has increased response rates to 60% to 70%, increasing the survival of patients with advanced colorectal cancer (5–7).”
Doleschal, B., Kirchweger, P., Schwendinger, S., Kupferthaler, A., Burghofer, J., Webersinke, G., Jukic, E., Wundsam, H., Biebl, M., Petzer, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231200462 · Cited by 5
IL6ST: A Novel Therapeutic Target for Managing and Treating Colorectal Cancer Via Ferroptosis
Zhao, K., He, B., Xue, K., Cao, B., Ren, K., Jin, Y., Rong, S., Wei, L.-Z., & Wei, H. (2024) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2024.23353 · Cited by 4
Xu, C., Ren, J., Liu, C., Gai, Y., Cheng, X., Wang, Y., & Wang, G. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001697 · Cited by 4
“However, the ORR reported in previous studies for both CAPEOX and FOLFOX plus cetuximab ranged between 57 and 72%, significantly higher than our study results [5,15,21,23 – 29].”
Advances in bevacizumab in colorectal cancer: a bibliometric analysis from 2004 to 2023
Chen, H., Lei, Y., Zhou, J., Lv, C., & Xuan, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1552914 · Cited by 4
Liu, Q., Liang, J., Gu, Y., Gao, H., Yang, D., Jiang, Y., Zhang, J., Lei, Q., & Yang, B. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114351 · Cited by 4
Nevala-Plagemann, C., Iyengar, S. K., Trunk, A. D., Pappas, L. M., Haaland, B. A., & Garrido‐Laguna, I. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7079 · Cited by 4
AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression
Wu, Q., Chen, J. D., & Zhou, Z. (2022) · Biological Procedures Online · doi:10.1186/s12575-021-00162-8 · Cited by 4
“For patients with metastatic CRC (mCRC), cetuximab (CTX), as an EGFR monoclonal antibody, is a typical anti-cancer therapeutic method to suppress cancer progression binding with traditional chemotherapy [15, 16].”
BackgroundThonhauser, R., Poglitsch, M., Jonas, J. P., Dong, Y., Tschögl, M., Gramberger, M., Salem, M., Santol, J., Brandl, I., Klimpfinger, M., et al. (2023) · Cancers · doi:10.3390/cancers15112900 · Cited by 4
“However, the American 80405 trial did not find any benefits in regard to response, recurrence-free survival (RFS), or OS when comparing these two strategies [9].”
Caughey, B. A., Umemoto, K., Green, M. F., Ikeda, M., Lowe, M. E., Ueno, M., Niedzwiecki, D., Taniguchi, H., Walden, D. J., Komatsu, Y., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-114 · Cited by 4
“Therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) alone or in combination with chemotherapy is an important therapeutic option in RAS / RAF wild-type (WT) CRC (4,5).”
Self-citationEmiloju, O. E., Zhu, M., Xie, H., Jin, Z., Sinicrope, F. A., & Hubbard, J. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01142-8 · Cited by 4
“…doublet chemotherapy (FOLFOX or FOL-FIRI) was evaluated in patients with KRAS exon 2 wt mCRC, but there were no significant differences in OS (30.0 vs 29.0 months; HR = 0.88; P = 0.08), PFS (10.5 vs 10.6 months; HR = 0.95; P = 0.45), or ORR (59.6% vs 55.2%; P = 0.13) between the two arms [51].”
InfluentialDing, Y., Han, X., Zhao, S., Wang, S., Guo, J., Leng, C., Li, X., Wang, K., Qiu, W., & Qi, W.-W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03513-5 · Cited by 4
“Presently, the rates of response for chemotherapy along with targeted therapy can be elevated to 60% in patients with initially unresectable CRLM [7, 8].”
Li, W.-H., Lan, J., Zhou, C., Yang, R., Wang, J., He, J.-H., Xiao, B.-Y., Ou, Q.-J., Fang, Y.-J., Fan, W., et al. (2024) · Annals medicus · doi:10.1080/07853890.2024.2396559 · Cited by 3
“…triplet chemotherapy regimens with targeted therapies including antiangiogenic therapy has increased the survival of patients with metastatic cRc [8,9], while intrinsic or acquired resistance seems inevitable and the overall benefit is still limited [10–12]. therefore, exploring novel…”
Valéry, M., Tanguy, M., Gelli, M., Smolenschi, C., Hollebecque, A., Boilève, A., de Sevilla, E. F., Tselikas, L., Bonnet, B., Goèré, D., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08807-6 · Cited by 4
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Fang, Y., Liu, Y., Dong, Z., Zhao, X., Zhang, M., Zheng, Y., Yang, C., Wang, Y., Liu, N., Yan, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75180-z · Cited by 4
Guo, H., Miao, L., & Yu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177219 · Cited by 4
Comparative and combined effectiveness of innovative therapies in cancer: a literature review
Geldof, T., Rawal, S., Dyck, W. V., & Huys, I. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0131 · Cited by 5
Ostwal, V. S., Kapoor, A., Engineer, R. Z., Saklani, A. P., Desouza, A. L., Patil, P. S., Arya, S., Ankathi, S. K., Chopra, S., Patil, M., et al. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_174_18 · Cited by 4
Signorelli, C., Gemma, D., Grande, R., Marco, S. D., Saltarelli, R., Morandi, M. G., Spinelli, G. P., Zoratto, F., Sperduti, I., Chilelli, M. G., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15033 · Cited by 4
Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
Elsamany, S. A., Elsisi, G. H., Hassanin, F., Saleh, K., & Tashkandi, E. M. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.07.001 · Cited by 4
China Working Group on Colorectal Cancer Survey, Zhang, X., Lian, X., Gu, X., Liu, Y., Feng, C.-Y., Li, L., Xu, H., Du, J.-C., Zhao, Y., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-988 · Cited by 4
“Monoclonal antibodies against epidermal growth factor receptors (EGFRs), such as cetuximab and panitumumab, have been proven to significantly improve overall survival (OS) in patients with advanced CRC (8,9).”
BackgroundWadd, N., Peedell, C., & Polwart, C. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.04.012 · Cited by 4
Shimozaki, K., Hirata, K., Sato, T., Nakamura, M., Kato, K., Hirano, H., Kumekawa, Y., Hino, K., Kawakami, K., Kito, Y., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.08.002 · Cited by 4
Cai, C., Luo, Q., Liu, Y., Peng, Y., Zhang, X., Jiang, Z., Feng, Z., Qi, Y., Gao, Y., Liu, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015510 · Cited by 4
“All other trials had at least one item with an unclear risk of bias (Heinemann et al., 2014; Cremolini et al., 2015; Rivera et al., 2017; Venook et al., 2017; Hurwitz et al., 2019).”
BackgroundInfluential
Metadata
- Authors
- Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., Berry, S., Polite, B. N., O'Reilly, E. M., Goldberg, R. M., Hochster, H. S., Schilsky, R. L., Bertagnolli, M. M., El-Khoueiry, A. B., Watson, P., Benson, A. B., Mulkerin, D. L., Mayer, R. J., & Blanke, C.
- Affiliations
- University of California, San Francisco (US)
- Duke University (US)
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Dana-Farber/Partners CancerCare, Boston, Massachusetts
- Indiana University, Simon Cancer Center, Indianapolis
- Southeastern Medical Oncology Center (US)
- Sunnybrook Health Science Centre (CA)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
- American Society of Clinical Oncology (US)
- Brigham and Women's Hospital (US)
- Kinston Medical Specialists (US)
- Northwestern University (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-20
- Volume
- 317
- Issue
- 23
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5545896
- OpenAlex
- W2712978371
- Cited by
- 898
- References
- 24
- Citations by year
- 2026: 66 · 2025: 76 · 2024: 87 · 2023: 104 · 2022: 118 · 2021: 118 · 2020: 122 · 2019: 107 · 2018: 82 · 2017: 16
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (U10CA180882, K05CA169384, U10CA180820, U10CA180791, U10CA180888, U10CA180836, U10CA180790, U10CA180830, U10CA180795, U10CA180850, R01CA149222, U10CA180838, U10CA180867, U10CA180821, U10CA180799)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type, cetuximab, bevacizumab, first-line chemotherapy, mFOLFOX6, FOLFIRI, oxaliplatin, irinotecan, monoclonal antibodies, overall survival, progression-free survival, anti-EGFR therapy, anti-VEGF therapy, community oncology
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Canada, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Genes, ras, United States, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
